Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms

Clinical Cancer Research

Volumn 22, Issue 7, 2016, Pages 1553-1558

  Kluetz, Paul G ^a   Slagle, Ashley ^a   Papadopoulos, Elektra J ^a   Johnson, Laura Lee ^a   Donoghue, Martha ^a   Kwitkowski, Virginia E ^a   Chen, Wen Hung ^a   Sridhara, Rajeshwari ^a   Farrell, Ann T ^a   Keegan, Patricia ^a   Kim, Geoffrey ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; ARTICLE; CANCER RESEARCH; CLINICAL ASSESSMENT TOOL; COGNITION; DISEASE ASSOCIATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; PATIENT INFORMATION; PATIENT REPORTED OUTCOME; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; SELF REPORT; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; WELLBEING; CLINICAL TRIAL (TOPIC); MORTALITY; NEOPLASMS; PATIENT-REPORTED OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE;

EID: 84964344844     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2035     Document Type: Article

References (23)

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
2. Common terminology criteria for adverse events (CTCAE) version 4.0 [PDF on the Internet]. Bethesda, MD: National Cancer Institute; 2001 [cited 2015 Jul 14]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5-7.pdf.
3. Guidance for industry: patient-reported outcome measures: use inmedical product development to support labeling claims [PDF on the internet]. Silver Spring, MD: U.S. Food and Drug Administration; 2009 [cited 2015 Jul 14]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.
4. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
5. Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res 1993;2:319-25.
6. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle M, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-46.
7. Basch E, Reeve BB, Mitchell SA, Clauser S, Minasian L, Dueck A, et al. Development of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer Inst 2014 Sep 29;106(9).
8. Jensen RE, Potosky AL, Reeve BB, Hahn E, Cella D, Fries J, et al. Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. Qual Life Res 2015;24:2333-44.
9. Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The imperative for a new approach to toxicity analysis in oncology clinical trials. J Natl Cancer Inst 2015 Aug 1;107(10).
10. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro K, Rogak L, et al. National Cancer Institute PRO-CTCAE Study Group. Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 2015;1:1051-9.
11. Donovan KA, Donovan HS, Cella D, Gaines M, Penson R, Plaxe S, et al. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst 2014 Jul 8;106(7).
12. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. B J Cancer 1993; 67:773-5.
13. Izano M, Satariano WA, Hiatt RA, Braithwaite D. The impact of functional limitations on long-term outcomes among African-American and white women with breast cancer: a cohort study. BMJ Open 2013;3:e003232.
14. Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware JE Jr. The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. J Clin Epidemiol 2014;67:516-26.
15. Petersen MA, Groenvold M, Aaronson NK, Chie W, Conroy T, Costantini A, et al. Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimension. Qual Life Res 2011;20:479-90.
16. Fouladiun M, Korner U, Gunnebo L, Sixt-Ammilon P, Bosaeus I, Lundholm K. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 2007;13:6379-85.
17. Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H, Lu H, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 2012;18:3212-7.
18. Chen RC, Chang P, Vetter RJ, Lukka H, Stokes W, Sanda M, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst 2014 Jul 8;106(7).
19. Chera BS, Eisbruch A, Murphy BA, Ridge J, Gavin P, Reeve BB, et al. Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. J Natl Cancer Inst 2014 Jul 8;106(7).
20. Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 2014 Jul 8;106(7).
21. Clinical outcome assessment qualification aubmissions [about 5 screens] [cited 2015 Jul 14]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm450689.htm.
22. The voice of the patient: lung cancer [PDF on the Internet]. Rockville, MD: U.S. Food and Drug Administration; 2013 [cited 2015 Aug 25]. Available from: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM379698.pdf.
23. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C; Clinical Significance Consensus Meeting, Group. Assessing the clinical significance of single items relative to summated scores. Mayo Clinic Proc 2002;77:479-87.